LIVINGSTON, N.J.--(BUSINESS WIRE)-- Columbia Laboratories, Inc. (Nasdaq: CBRX) has renewed its license and supply agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for CRINONE ...
- Established, patient-preferred infertility treatment - - Expands Watson's Women's Health brand product portfolio - - Preterm birth clinical trials currently underway - - Company acquires 11.2 ...
Value of deal could nearly double if Prochieve is approved for additional indication. Watson Pharmaceuticals is paying Columbia Laboratories $47 million up front for all the latter’s progesterone ...
“Our progesterone business grew nicely in the second quarter and first half of 2010,” said Frank C. Condella, Jr., Columbia’s president and chief executive officer. “With the close of the Watson ...
LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (Nasdaq: CBRX) has amended its license and supply agreement with Merck Serono, a division of Merck KGaA (XETRA: MRK.DE), Darmstadt, ...
Co announces that an interim analysis of a pregnancy study comparing the efficacy of Crinone 8% to compounded intramuscular progesterone injections is now available online and will be published in ...
<0> Columbia Laboratories, Inc.Lawrence A. Gyenes, 973-486-8860Senior Vice President, CFO & TreasurerorThe Trout Group LLCSeth Lewis, 646-378-2952Vice President </0> Columbia Laboratories, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback